Methotrexate Elimination in a Patient with an Orthotopic Neobladder with and without a Urethral Catheter

Authors:
  • RDRobert E. Dupuis
    Robert E. Dupuis
  • JMJames L. Mohler
    James L. Mohler
  • SBStephen A. Bernard
    Stephen A. Bernard
  • CLCeleste M. Lindley
    Celeste M. Lindley

Abstract
Placement of a urethral catheter has been recommended to ensure adequate methotrexate elimination in patients with a neobladder; however, the need for this and its impact on methotrexate elimination have not been determined. A 53‐year‐old man with a cecal continent urinary diversion received intravenous methotrexate 30 mg/m2 on two occasions, with and without urethral catheter drainage of the neobladder. Serum methotrexate concentrations declined at a rate that resulted in 24‐ and 48‐hour values falling below the accepted toxic concentration threshold of 5–50 μmol/L and 0.05 μmol/L, respectively. In this man, who received low‐dose methotrexate, catheterization of the neobladder did not alter methotrexate elimination sufficiently to justify its cost, risk, and inconvenience.

This publication has 10 references indexed in Scilit: